Search

Your search keyword '"Séamus, Hussey"' showing total 17 results
Start Over Author "Séamus, Hussey"
17 results on '"Séamus, Hussey"'

1. Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis—Caveat Emptor

Author

Lorraine Stallard and Séamus Hussey

Subjects
ulcerative colitis, pediatrics, endoscopy, histology, mucosal healing, Pediatrics, RJ1-570
Abstract

The impact of endoscopic and histological mucosal healing on outcomes in adult settings is impressive. Despite many clinical parallels, pediatric ulcerative colitis (UC) is set apart from adult disease in several respects. Many frequently used indices are not fully validated, especially in pediatric settings, and consensus on precise definitions in clinical settings are lacking. Endoscopic mucosal healing is an acceptable long-term treatment goal in pediatrics, but not histologic normalization. Early prediction of disease course in UC may allow treatment stratification of patients according to risks of relapse, acute severe colitis, and colectomy. Putative endoscopic and histologic predictors of poor clinical outcomes in adults have not held true in pediatric settings, including baseline endoscopic extent, endoscopic severity, and specific histologic characteristics which are less prevalent in pediatrics at diagnosis. In this mini-review we appraise predictive endoscopic and histologic factors in pediatric UC with reference to relapse, severe colitis, and colectomy risks. We recommend that clinicians routinely use endoscopic and histologic sores to improve the quality of clinical and research practice. The review summarizes differences between adult and pediatric prediction data, advises special consideration of those with primary sclerosing cholangitis, and suggests areas for future study in this field.

Published
2021
Full Text
View/download PDF

2. The Oral Microbiome in Pediatric IBD: A Source of Pathobionts or Biomarkers?

Author

Khalid Elmaghrawy, Séamus Hussey, and Gary P. Moran

Subjects
inflammatory bowel disease, Crohn's disease, ulcerative colitis, microbiome, dysbiosis, inflammation, Pediatrics, RJ1-570
Abstract

The oral cavity is continuous with the gastrointestinal tract and in children, oral health may be closely linked with the overall health of the GI tract. In the case of pediatric Crohn's disease (CD), oral manifestations are an important clinical indicator of intestinal disease. Recent studies of the microbiome in IBD suggest that translocation of oral microbes to the gut may be a common feature of the microbial dysbiosis which is a signature of both CD and ulcerative colitis (UC). Murine studies suggest that translocation of oral bacteria and yeasts to the lower GI tract may trigger inflammation in susceptible hosts, providing a mechanistic link to the development of IBD. Conversely, some studies have shown that dysbiosis of the oral microbiome may occur, possibly as a result of inflammatory responses and could represent a useful source of biomarkers of GI health. This review summarizes our current knowledge of the oral microbiome in IBD and presents current hypotheses on the potential role of this community in the pathogenesis of these diseases.

Published
2021
Full Text
View/download PDF

4. The Oral Microbiome in Treatment-Naïve Paediatric IBD Patients Exhibits Dysbiosis Related to Disease Severity that Resolves Following Therapy

Author

Khalid Elmaghrawy, Paddy Fleming, Kirsten Fitzgerald, Sarah Cooper, Anna Dominik, Séamus Hussey, and Gary P Moran

Subjects
Gastroenterology, General Medicine
Abstract

Background There is a limited literature describing the oral microbiome and its diagnostic potential in paediatric inflammatory bowel disease [IBD]. Methods We examined the dorsum tongue microbiome by V1–V2 sequencing in a cohort of 156 treatment-naïve children diagnosed with IBD compared to 102 healthy control children. Microbiome changes over time following treatment were examined in a subset of patients and associations between IBD diagnosis and dysbiosis were explored. Results Analysis of community structure of the microbiome in tongue samples revealed that IBD samples diverged significantly from healthy control samples [PERMANOVA p = 0.0009] and exhibited a reduced abundance of Clostridia in addition to several major oral genera [Veillonella, Prevotella and Fusobacterium species] with an increased abundance of streptococci. This dysbiosis was more marked in patients with severe disease. Higher levels of the potential pathobionts Klebsiella and Pseudomonas spp. were also associated with IBD. In terms of predicted functions, the IBD oral microbiome was potentially more acidogenic and exhibited reduced capacity for B vitamin biosynthesis. We used a machine learning approach to develop a predictive model of IBD which exhibited a mean-prediction AUC [area under the ROC curve] of 0.762. Finally, we examined a subset of 53 patients following 12 months of therapy and could show resolution of oral dysbiosis as demonstrated by a shift towards a healthy community structure and a significant reduction in oral dysbiosis. Conclusion Oral dysbiosis found in children with IBD is related to disease severity and resolves over time following successful IBD treatment.

Published
2022
Full Text
View/download PDF

7. Anorexia Nervosa Complicating Pediatric Crohn Disease—Case Report and Literature Review

Author

Aedin Collins, Elizabeth Nolan, Michelle Hurley, Antoinette D'Alton, and Séamus Hussey

Subjects
Crohn disease, adolescent, anorexia nervosa, BMI, weight loss, Pediatrics, RJ1-570
Abstract

Crohn disease and anorexia nervosa share common symptoms of weight loss and reduced oral intake. The prevalence of both disorders has increased over time. Symptoms of Crohn disease and anorexia nervosa can mimic each other leading to a delayed diagnosis and requiring complex, multidisciplinary management. Here we present a case of a 15 year old girl with Crohn disease who subsequently developed anorexia nervosa, and review the published literature on the occurrence of both diagnoses.

Published
2018
Full Text
View/download PDF

8. Outcomes of a National Cohort of Children with Acute Severe Ulcerative Colitis

Author

Abisoye O. Akintimehin, Ríoghnach Sinead O’Neill, Conor Ring, Tara Raftery, and Séamus Hussey

Subjects
acute, severe, ulcerative, colitis, infliximab, children, Pediatrics, RJ1-570
Abstract

AimAll Irish children with ulcerative colitis (UC) attend the National Centre for Paediatric Gastroenterology at Our Lady’s Children’s Hospital, Crumlin. The aim of this study was to determine the outcomes of children with acute severe ulcerative colitis (ASC) and the impact of infliximab on these outcomes following its introduction for this indication in 2011.MethodsA retrospective chart review of all patients admitted with ASC between January 1, 2009 and December 31, 2015 was undertaken. Patients were identified from the departmental database cross-referenced with the hospital inpatient enquiry system. Inpatients with a paediatric ulcerative colitis activity index (PUCAI) of ≥65 were included. Data collected included baseline demographic and laboratory data, concomitant treatments, PUCAI scores on days 3 and 5, second-line treatments, surgery, and discharge outcomes. Infliximab dose, frequency, and available therapeutic drug monitoring results were recorded, along with clinical response outcomes (remission, primary, and secondary loss of response). The cohort was sub-analysed to determine if there was any era effect pre- and post-introduction of infliximab (2009–2010 and 2011–2015, respectively).ResultsFifty-five patients (M:F = 1.4:1) were treated for acute severe colitis over the study period (8 in the pre-infliximab and 47 in the post-infliximab era) and 46/55 (86%) had steroid-refractory disease. Of these, 7/8 (88%) required colectomy in the pre-infliximab era, compared with 15/47 (36%) in the post-infliximab era. The remission rate with second-line infliximab was 61% at maximal follow-up. There were no identifiable factors that predicted likely success or failure of infliximab, including gender, CRP, day-3 and day-5 PUCAI scores. Of the 33 patients treated with infliximab, dose increase was required in 23/33 (70%); 21/33 (64%) received an accelerated dose schedule, and 9/33 (27%) eventually needed colectomy. Primary and secondary loss of response to infliximab was seen in one and nine patients, respectively.ConclusionThis is the first population-based study of the outcomes of severe UC in Irish children, and suggests a higher burden of steroid-refractory disease compared with previous international studies. While infliximab treatment has led to reduction in colectomy rates, a significant proportion of patients lose therapeutic effect.

Published
2018
Full Text
View/download PDF

9. Development and Validation of the TUMMY-UC: A Patient-Reported Outcome for Pediatric Ulcerative Colitis

Author

Liron Marcovitch, Gili Focht, Natalie Carmon, Claudia Tersigni, Oren Ledder, Raffi Lev-Tzion, Peter C. Church, Jeffrey S. Hyams, Robert N. Baldassano, Athos Bousvaros, David R. Mack, Séamus Hussey, Anthony Otley, Nicholas M. Croft, Michael D. Kappelman, Anne M. Griffiths, and Dan Turner

Subjects
Hepatology, Gastroenterology
Abstract

The TUMMY-UC is a Patient Reported Outcome (PRO) measure for pediatric ulcerative colitis (UC) with an observer RO (obsRO) version for children8 years. It includes eight items selected by concept elicitation interviews. We aimed to finalize the TUMMY-UC by cognitive interviews (stage-2) and to evaluate the index for its psychometric properties (stage-3).The TUMMY-UC items were first finalized during 129 cognitive debriefing interviews. Then, in a prospective-multicenter validation study, 84 children who either underwent colonoscopy or provided stool for calprotectin completed the TUMMY-UC and various measures of disease activity. Assessments were repeated after 7 and 21 days for evaluating reliability and responsiveness.During stage-2, the items were formatted with identical structure to ensure conceptual equivalence, and weighted based on ranking of importance. In stage-3, the TUMMY-UC total score had excellent reliability in repeated assessments (intraclass correlation coefficient [ICC], 0.90 [95%CI 0.84-0.94]). It also had moderate to strong correlations with all constructs of disease activity: r=0.70 with UC endoscopic index of severity, r=0.63 with IMPACT questionnaire, r=0.43 with calprotectin, r=0.80 with the PUCAI, r=0.75 with global assessment of disease activity and r=0.46 with C-reactive protein (all p0.015). The index had excellent discrimination of disease activity with a score9 defining remission (AUROC=0.95 (95%CI 0.93-0.99)). The ΔTUMMY-UC showed high responsiveness and differentiated well between children who experienced changed from those with no change.The TUMMY-UC, constructed from PRO and ObsRO versions, is a reliable, valid and responsive index, which can be now used in practice and clinical trials.

Published
2023
Full Text
View/download PDF

10. Contributors

Author

H. Hesham A-Kader, Sophia Abdulhai, Kareem Abu-Elmagd, Maisam Abu-El-Haija, Douglas G. Adler, Lindsey Albenberg, Estella M. Alonso, Ruchi Amin, Orhan Atay, Renata Auricchio, Robert D. Baker, Susan S. Baker, Katherine Baldwin, Jessica Barry, Todd H. Baron, Bradley Barth, Dorsey M. Bass, Lee M. Bass, Jaime Belkind-Gerson, Marc A. Benninga, Natalie Bhesania, Andrea Bischoff, Samuel Bitton, Samra S. Blanchard, Athos Bousvaros, Brendan Boyle, Jennifer Brewer, Jefferson N. Brownell, Steven W. Bruch, Brendan T. Campbell, Jacob Campbell, Michael Gerard Caty, Carolina S. Cerezo, Ryaz Chagpar, Beth Chatfield, Rebecca N. Cherry, Gail Cohen, Mitchell B. Cohen, Arnold G. Coran, Guilherme Costa, Gail A.M. Cresci, Eileen Crowley, Michael Cruise, Steven J. Czinn, Zev Davidovics, Luis De La Torre, Anthony L. DeRoss, David Devadason, Rajitha Devadoss Venkatesh, Carlo Di Lorenzo, Jennifer L. Dotson, Tracy R. Ediger, Bijan Eghtesad, John F. Eisses, Mounif El Yousif, Karan McBride Emerick, Steven H. Erdman, Rima Fawaz, Ariel E. Feldstein, Melissa Fernandes, Laura S. Finn, Kristin Nicole Fiorino, Douglas S. Fishman, Joel A. Friedlander, Masato Fujiki, John Fung, Ivan Fuss, David Galloway, Donald E. George, Fayez K. Ghishan, Raffaelle Girlanda, Donna Gitt, Deborah A. Goldman, Sue Goodine, Glenn R. Gourley, Nicole Green, Gabrielle Grisotti, Sandeep K. Gupta, Nedim Hadzic, Sanjiv Harpavat, Koji Hashimoto, Maheen Hassan, James E. Heubi, Sohail Z. Husain, Séamus Hussey, Jeffrey S. Hyams, Warren Hyer, Paul E. Hyman, Sabine Iben, Veronica E. Issac, Maureen M. Jonas, Marsha Kay, Mohit Kehar, Deidre Kelly, Karlo Kovacic, Shaun Michael Kunisaki, Jacob A. Kurowski, Jacob C. Langer, Frances C. Lee, Rose Lee, Neal S. LeLeiko, Chris A. Liacouras, Henry Lin, Quin Y. Liu, Kathleen M. Loomes, Peter L. Lu, Sarah Shrager Lusman, Cara Mack, Anshu Maheshwari, Petar Mamula, Michael A. Manfredi, James F. Markowitz, Jonathan E. Markowitz, Maria R. Mascarenhas, Ryann Mayer, Patrick McKiernan, Adam G. Mezoff, Ethan A. Mezoff, Giorgina Mieli-Vergani, Franziska Mohr, Jasmeet Mokha, Hayat Mousa, Lindsay Moye, Simon Murch, Karen F. Murray, Robert Naples, Jaimie D. Nathan, Vicky Lee Ng, Vi Nguyen, Samuel Nurko, Jodie Oauhed, Tina Ogholikhan, Keith T. Oldham, Mohammed Osman, Nadia Ovchinsky, Jennifer Panganiban, Alberto Pena, Robert E. Petras, Marian D. Pfefferkorn, David Piccoli, Travis Piester, Beth Pinkos, Thomas Plesec, Stephanie Polites, Todd Ponsky, Christine Rader, Kadakkal Radhakrishnan, Yannis Reissis, Leonel Rodriguez, Ricardo J. Rodriguez, Isabel Rojas, Ellen S. Rome, Joel R. Rosh, Rachel M. Ruiz, Benjamin Sahn, Atif Saleem, Kate A. Samela, Neha R. Santucci, Miguel Saps, Eleanor H. Sato, Thomas T. Sato, Erica C. Savage, Federico G. Seifarth, Praveen Kumar Conjeevaram Selvakumar, Jason Shapiro, Allan E. Siperstein, Joseph Skelton, Scott Snapper, Oliver S. Soldes, Manu R. Sood, Marisa Gallant Stahl, Shikha S. Sundaram, Francisco A. Sylvester, Jonathan E. Teitelbaum, Natalie A. Terry, Peter Townsend, Riccardo Troncone, Kate Vance, Yvan Vandenplas, Robert S. Venick, David S. Vitale, Jerry Vockley, Eugene Vortia, Mana H. Vriesman, Ghassan T. Wahbeh, R. Matthew Walsh, Suz Warner, Robert Wyllie, Jessica L. Yasuda, Donna Zeiter, and Hengqi (Betty) Zheng

Published
2021
Full Text
View/download PDF

12. 983: OUTCOME OF INDUCTION THERAPY WITH VEDOLIZUMAB IN CHILDREN: RESULTS FROM THE PROSPECTIVE, MULTICENTER, VEDOKIDS STUDY

Author

Zivia Shavit-Brunschwig, Ronen E. Stein, Marina Aloi, Oren Ledder, Gili Focht, Darja Urlep, Jeffrey S. Hyams, Efrat Broide, Batia Weiss, Jeremiah Levine, Dror Shouval, Manar Matar, Amit Assa, Joel R. Rosh, Séamus Hussey, James Markowitz, Anat Yerushalmy-Feler, Erasmo Miele, Ron Shaoul, Richard K. Russell, and Dan Turner

Subjects
Hepatology, Gastroenterology
Published
2022
Full Text
View/download PDF

13. Parenteral Antibiotics Reduce Bifidobacteria Colonization and Diversity in Neonates

Author

Séamus Hussey, Rebecca Wall, Emma Gruffman, Lisa O'Sullivan, C. Anthony Ryan, Brendan Murphy, Gerald Fitzgerald, Catherine Stanton, and R. Paul Ross

Subjects
Microbiology, QR1-502
Abstract

We investigated the impact of parenteral antibiotic treatment in the early neonatal period on the evolution of bifidobacteria in the newborn. Nine babies treated with intravenous ampicillin/gentamicin in the first week of life and nine controls (no antibiotic treatment) were studied. Denaturing gradient gel electrophoresis was used to investigate the composition of Bifidobacterium in stool samples taken at four and eight weeks. Bifidobacteria were detected in all control infants at both four and eight weeks, while only six of nine antibiotic-treated infants had detectable bifidobacteria at four weeks and eight of nine at eight weeks. Moreover, stool samples of controls showed greater diversity of Bifidobacterium spp. compared with antibiotic-treated infants. In conclusion, short-term parenteral antibiotic treatment of neonates causes a disturbance in the expected colonization pattern of bifidobacteria in the first months of life. Further studies are required to probiotic determine if supplementation is necessary in this patient group.

Published
2011
Full Text
View/download PDF

15. Contributors

Author

H. Hesham A-Kader, Sabina Ali, Naim Alkhouri, Estella M. Alonso, Rana Ammoury, Marjorie J. Arca, Arthur B. Atlas, Salvatore Auricchio, Robert D. Baker, Susan S. Baker, Todd H. Baron, Brad Barth, Dorsey M. Bass, Phyllis R. Bishop, Samra S. Blanchard, Louisa W. Chiu, Dennis L. Christie, Gail M. Cohen, Mitchell B. Cohen, Stanley A. Cohen, Claudia Conkin, Arnold G. Coran, Laura L. Cushman, Athos Bousvaros, John T. Boyle, Steven W. Bruch, Brendan T. Campbell, Anthony Capizzani, Christine Carter-Kent, Michael G. Caty, Mounif El-Youssef, Karan McBride Emerick, Jonathan Evans, Rima Fawaz, Ariel E. Feldstein, Laura S. Finn, Douglas S. Fishman, Steven J. Czinn, David Devadason, Carlo Di Lorenzo, Ranjan Dohil, Maryanne L. Dokler, Marla Dubinsky, Bijan Eghtesad, Peter F. Ehrlich, José M. Garza, Michael W.L. Gauderer, Donald E. George, Fayez K. Ghishan, Mark A. Gilger, Laura Gillespie, Elizabeth Gleghorn, Joseph F. Fitzgerald, David R. Fleisher, Jacqueline L. Fridge, Joel Friedlander, Judy Fuentebella, John J. Fung, Jennifer Garcia, Reinaldo Garcia-Naveiro, Glenn R. Gourley, Richard J. Grand, Reema Gulati, Sandeep K. Gupta, Nedim Hadžic´, Eric Hassall, James E. Heubi, Vera F. Hupertz, Sohail Z. Husain, Séamus Hussey, Jeffrey S. Hyams, Warren Hyer, Paul E. Hyman, Sabine Iben, Kishore R. Iyer, Benjamin R. Kuhn, Marc A. Levitt, Shane D. Lewis, Bu K. Li, Chris A. Liacouras, Danny C. Little, Maureen M. Jonas, Nicola L. Jones, Barbara Kaplan, Stuart S. Kaufman, Marsha Kay, Deirdre Kelly, Samuel A. Kocoshis, Jonathan E. Markowitz, Maria R. Mascarenhas, Peter Mattei, Valérie A. McLin, Adam G. Mezoff, Giorgina Mieli-Vergani, Tracie L. Miller, Vera Loening-Baucke, Kathleen M. Loomes, Mark E. Lowe, David K. Magnuson, Lori A. Mahajan, Petar Mamula, James F. Markowitz, Franziska Mohr, Robert K. Montgomery, Kathleen J. Motil, Simon Murch, Karen F. Murray, Hillel Naon, Aruna S. Navathe, Vicky Lee Ng, Scott Nightingale, Michael J. Nowicki, Samuel Nurko, Keith T. Oldham, Alberto Peña, Robert E. Petras, Marian D. Pfefferkorn, Sarah M. Phillips, Cary Qualia, Shervin Rabizadeh, Kadakkal Radhakrishnan, Leonel Rodriguez, Ricardo Rodriguez, Ellen S. Rome, Joel R. Rosh, Colin D. Rudolph, Daniel F. Saad, Shehzad A. Saeed, Atif Saleem, Bhupinder Sandhu, Miguel Saps, Thomas T. Sato, Harohalli Shashidhar, Noah F. Shroyer, Joseph Skelton, Lesley Smith, Hiroshi Sogawa, Oliver S. Soldes, Manu R. Sood, Rita Steffen, Kara M. Sullivan, Shikha S. Sundaram, Bhanu K. Sunku, Francisco A. Sylvester, Jan Taminiau, Jonathan E. Teitelbaum, Daniel W. Thomas, Mike A. Thomson, Vasundhara Tolia, William R. Treem, Riccardo Troncone, Aaron Turkish, John N. Udall, Yvan Vandenplas, Gigi Veereman-Wauters, Ghassan T. Wahbeh, Elizabeth C. Wallace, R. Matthew Walsh, Anna Wieckowska, Charles G. Winans, Robert Wyllie, Sani Z. Yamout, and Nada Yazigi

Published
2011
Full Text
View/download PDF

16. Helicobacter pylori infection and childhood

Author

Petronella, Mourad-Baars, Séamus, Hussey, and Nicola L, Jones

Subjects
Family Health, Antigens, Bacterial, Genomic Islands, Helicobacter pylori, Virulence Factors, Probiotics, Helicobacter Infections, Middle East, Treatment Outcome, Bacterial Proteins, Child, Preschool, Prevalence, Humans, Child
Abstract

Pediatric-based Helicobacter pylori research continues to contribute significantly to our understanding of both clinical and pathophysiological aspects of this infection. Here, we review the published pediatric H. pylori literature from April 2009-March 2010. Analysis of pediatric H. pylori strains continues to suggest that cagA(+) and cagPAI competent strains are less prevalent than in adult isolates. Studies from the Middle East report a high H. pylori prevalence and intrafamilial transmission. Data continue to show a lack of association between H. pylori and recurrent abdominal pain of childhood, gastroesophageal reflux disease, and growth retardation. Recent probiotic trials have not shown a benefit on H. pylori eradication in children, while sequential therapy remains an attractive therapeutic eradication strategy in children, which requires validation in different geographic regions.

Published
2010

17. Genomic diversity of cultivable Lactobacillus populations residing in the neonatal and adult gastrointestinal tract

Author

Rebecca, Wall, Gerald, Fitzgerald, Séamus, Hussey, Tony, Ryan, Brendan, Murphy, Paul, Ross, and Catherine, Stanton

Subjects
Adult, Male, Adolescent, Age Factors, Infant, Newborn, Genetic Variation, Infant, Electrophoresis, Gel, Pulsed-Field, Gastrointestinal Tract, Feces, Lactobacillus, RNA, Ribosomal, 16S, Humans, Female, Child, Genome, Bacterial
Abstract

The objective of this study was to investigate the cultivable Lactobacillus population in adult and infant faecal material to identify strains shared across a number of individuals. A range of lactobacilli isolated on Lactobacillus-selective agar from faeces of 16 infants and 11 adults were genetically fingerprinted and further characterized by 16S rRNA gene sequencing. The relatedness of all the Lactobacillus strains isolated to known species was also determined both genetically and phenotypically. This study revealed that the human intestine is initially colonized by only a few (1-2) different cultivable strains whereas in adults the pattern becomes more complex with a higher diversity of strains. The adult samples contained three genetically distinct Lactobacillus strains in some cases, while infant samples generally harboured only one dominant Lactobacillus strain. Moreover, the species in general appeared to differ with Lactobacillus rhamnosus and Lactobacillus casei/paracasei found mainly in adults, whereas Lactobacillus gasseri and Lactobacillus salivarius were more commonly isolated in infant samples. The data reaffirm the differences in Lactobacillus populations both between individual subjects and between the infant and adult, with an overall change in the diversity and complexity from early stages of life to adulthood.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results